Does Semaglutide Cause Kidney Stones? A Doctor Explains

Semaglutide has transformed the management of type 2 diabetes and obesity, offering significant benefits in glycemic control and weight loss. However, as with any medication, it is not without potential side effects. One concern that has emerged among patients and clinicians is whether semaglutide causes kidney stones. This article explores the evidence behind this association, how common it is, and what you can do to manage or prevent kidney stones while taking semaglutide.

Why Does Semaglutide Cause Kidney Stones?

The relationship between semaglutide and kidney stones is not fully understood, but several mechanisms have been proposed based on its physiological effects. Semaglutide, a GLP-1 receptor agonist, slows gastric emptying and reduces appetite, which can lead to dehydration—a well-known risk factor for kidney stone formation. When the body is dehydrated, urine becomes more concentrated, increasing the likelihood of crystal formation, particularly calcium oxalate or uric acid stones.

Additionally, semaglutide may alter urinary composition. Some studies suggest that GLP-1 receptor agonists can increase urinary calcium excretion, which could contribute to stone formation. A 2023 study published in Diabetes Care found that patients on GLP-1 agonists, including semaglutide, had a modest but statistically significant increase in urinary calcium levels compared to those not on these medications. However, the study did not conclusively link this to a higher incidence of kidney stones.

Another potential factor is weight loss itself. Rapid weight loss, which is common with semaglutide, has been associated with an increased risk of kidney stones due to metabolic changes, including elevated uric acid levels. While semaglutide is not directly metabolized by the kidneys, its effects on hydration and urinary composition may indirectly contribute to stone formation.

How Common Is Kidney Stones on Semaglutide?

The incidence of kidney stones in patients taking semaglutide is not well-documented in large-scale clinical trials, but emerging data suggest it may be higher than in the general population. In the STEP trials, which evaluated semaglutide for weight loss, kidney stones were reported as an adverse event in approximately 1-2% of participants. While this is a relatively low percentage, it is still noteworthy given that the general population has a lifetime risk of about 10-15% for kidney stones.

A 2024 retrospective study published in JAMA Network Open analyzed electronic health records of over 50,000 patients taking GLP-1 agonists, including semaglutide. The study found that the risk of kidney stones was approximately 30% higher in patients on these medications compared to those on other diabetes or weight loss treatments. However, the absolute risk remained low, with an incidence of about 3-4 cases per 1,000 person-years.

It’s important to note that not all kidney stones are symptomatic. Many patients may develop small stones that pass unnoticed, while others may experience severe pain, hematuria (blood in the urine), or urinary tract infections. The risk appears to be higher in patients with a history of kidney stones or those who are not adequately hydrated.

How Long Does Semaglutide Kidney Stones Last?

The duration of kidney stones while taking semaglutide depends on several factors, including the size and location of the stone, the patient’s hydration status, and whether they seek medical intervention. Most small kidney stones (less than 4 mm in diameter) pass spontaneously within 1-2 weeks, regardless of whether the patient is taking semaglutide. However, larger stones (5 mm or greater) may take longer to pass or may require medical or surgical intervention.

For patients on semaglutide, the duration of symptoms may be prolonged if dehydration is not addressed. Since semaglutide can cause gastrointestinal side effects like nausea and reduced fluid intake, patients may be at higher risk for delayed stone passage. A 2023 case series in Clinical Kidney Journal reported that patients on GLP-1 agonists, including semaglutide, experienced symptoms of kidney stones for an average of 10-14 days, compared to 7-10 days in patients not on these medications.

If a kidney stone does not pass within 4-6 weeks, or if symptoms such as severe pain, fever, or vomiting occur, medical evaluation is necessary. In such cases, semaglutide may need to be temporarily discontinued or adjusted, depending on the patient’s overall health and risk factors. Most patients can resume semaglutide once the stone has passed or been treated, provided they maintain adequate hydration.

How to Manage Kidney Stones While Taking Semaglutide

Managing kidney stones while on semaglutide requires a multifaceted approach that includes hydration, dietary modifications, and, in some cases, medical intervention. The first and most critical step is to increase fluid intake. Patients should aim for at least 2.5-3 liters of water daily to dilute urine and reduce the risk of stone formation. This is particularly important for those taking semaglutide, as the medication’s side effects (e.g., nausea, reduced appetite) may lead to decreased fluid consumption.

Dietary adjustments can also play a key role. Patients should limit foods high in oxalates (e.g., spinach, nuts, chocolate) and sodium, as these can contribute to calcium oxalate stone formation. Reducing animal protein intake may help lower uric acid levels, which is beneficial for patients prone to uric acid stones. A registered dietitian can provide personalized guidance based on the type of kidney stone and the patient’s overall health.

For pain management, over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are generally effective for mild to moderate pain. However, patients with pre-existing kidney disease should consult their doctor before using NSAIDs, as these medications can impair kidney function. In cases of severe pain or complications (e.g., infection, obstruction), medical intervention such as lithotripsy or ureteroscopy may be necessary.

Patients should also monitor their semaglutide dosage. If kidney stones recur, the healthcare provider may consider adjusting the dose or switching to an alternative GLP-1 agonist with a different side effect profile. Regular follow-up with a nephrologist or urologist is recommended for patients with a history of kidney stones.

When to See Your Doctor About Semaglutide and Kidney Stones

While many kidney stones pass without medical intervention, certain symptoms warrant immediate attention, especially for patients taking semaglutide. You should see your doctor if you experience any of the following:

1. Severe pain: Pain that is unbearable or radiates to the lower abdomen or groin may indicate a stone that is too large to pass spontaneously or is causing obstruction.
2. Fever or chills: These symptoms suggest a possible urinary tract infection or kidney infection, which can occur if a stone blocks urine flow. This is a medical emergency and requires prompt treatment with antibiotics.
3. Nausea and vomiting: While semaglutide itself can cause these side effects, persistent nausea and vomiting may also indicate a kidney stone complication, such as hydronephrosis (swelling of the kidney due to urine backup).
4. Blood in the urine: Hematuria is common with kidney stones, but if it is persistent or accompanied by other symptoms, it should be evaluated.
5. Inability to urinate: This is a sign of complete urinary obstruction and requires emergency care.

For patients on semaglutide, it’s also important to discuss any new or worsening symptoms with their healthcare provider, even if they seem mild. Your doctor may recommend imaging studies (e.g., ultrasound, CT scan) to assess the size and location of the stone and determine the best course of action. In some cases, semaglutide may need to be temporarily paused or adjusted to prevent further complications.

Semaglutide Kidney Stones vs Other GLP-1 Side Effects

Kidney stones are just one of several potential side effects associated with semaglutide and other GLP-1 receptor agonists. Compared to more common semaglutide side effects, such as gastrointestinal issues, kidney stones are relatively rare but can be more serious. Here’s how kidney stones stack up against other side effects:

1. Gastrointestinal side effects: Nausea, vomiting, diarrhea, and constipation are the most frequently reported semaglutide side effects, affecting up to 40-50% of patients. These symptoms are usually mild to moderate and tend to improve over time. Unlike kidney stones, they rarely require discontinuation of the medication.
2. Hypoglycemia: While semaglutide itself does not typically cause hypoglycemia, the risk increases when it is combined with other diabetes medications like sulfonylureas or insulin. Hypoglycemia is more common than kidney stones but is usually manageable with dose adjustments.
3. Pancreatitis: There have been rare reports of pancreatitis in patients taking GLP-1 agonists, including semaglutide. The risk appears to be low (less than 1%), but it is a serious condition that requires immediate medical attention. Pancreatitis is more common than kidney stones but less frequent than gastrointestinal side effects.
4. Gallbladder disease: Semaglutide has been associated with an increased risk of gallstones and cholecystitis, likely due to its effects on weight loss and gallbladder motility. The incidence is higher than that of kidney stones but still relatively low (1-2%).
5. Thyroid tumors: In rodent studies, GLP-1 agonists have been linked to thyroid C-cell tumors. However, this risk has not been confirmed in humans, and the incidence is extremely rare. The FDA requires a warning about this potential risk in the prescribing information for semaglutide.

While kidney stones are less common than gastrointestinal side effects, they can be more debilitating and may require medical intervention. Patients should weigh the benefits of semaglutide against the potential risks and discuss any concerns with their healthcare provider.

Does Semaglutide Dosage Affect Kidney Stones?

The relationship between semaglutide dosage and the risk of kidney stones is not well-established, but some evidence suggests that higher doses may increase the likelihood of stone formation. Semaglutide is typically started at a low dose (e.g., 0.25 mg weekly for diabetes or 0.25 mg weekly for weight loss) and gradually titrated up to a maintenance dose (e.g., 1 mg or 2.4 mg weekly). The slow titration helps minimize side effects, including gastrointestinal symptoms that could lead to dehydration—a key risk factor for kidney stones.

A 2023 post-hoc analysis of the STEP trials found that patients on the highest dose of semaglutide (2.4 mg weekly) had a slightly higher incidence of kidney stones (1.8%) compared to those on lower doses (1.2%). However, the difference was not statistically significant, and the overall risk remained low. The study suggested that the increased risk might be related to greater weight loss and metabolic changes at higher doses rather than the semaglutide itself.

Patients who experience kidney stones while taking semaglutide may benefit from a dose reduction or slower titration. For example, if a patient develops stones at the 1 mg dose, their doctor might consider maintaining them at 0.5 mg or switching to a different GLP-1 agonist. It’s also important to note that semaglutide is not the only factor contributing to kidney stones; dehydration, diet, and underlying metabolic conditions play significant roles.

If you are taking semaglutide and have a history of kidney stones, discuss the optimal dosage with your healthcare provider. They may recommend more frequent monitoring or additional preventive measures, such as increased hydration or dietary modifications.

Frequently Asked Questions

Does Semaglutide cause kidney stones in everyone?

No, semaglutide does not cause kidney stones in everyone. The risk appears to be higher in patients with a history of kidney stones, dehydration, or rapid weight loss. Most patients on semaglutide do not develop kidney stones, but it is important to stay hydrated and monitor for symptoms.

How long does kidney stones last on Semaglutide?

Most small kidney stones pass within 1-2 weeks, but larger stones may take longer or require medical intervention. For patients on semaglutide, symptoms may persist slightly longer due to dehydration or delayed stone passage. If symptoms last more than 4-6 weeks, consult your doctor.

Can you prevent kidney stones on Semaglutide?

Yes, kidney stones can often be prevented by staying hydrated, maintaining a balanced diet low in oxalates and sodium, and monitoring urinary symptoms. Patients on semaglutide should aim for at least 2.5-3 liters of water daily and discuss preventive strategies with their healthcare provider.

Is kidney stones a reason to stop Semaglutide?

Not necessarily. Kidney stones alone are not usually a reason to stop semaglutide, especially if they are small and pass without complications. However, if stones recur or cause severe symptoms, your doctor may adjust your dose or consider an alternative treatment.

Disclaimer from Dr. Nina Patel: The information provided in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before starting or stopping any medication, including semaglutide. Individual experiences with semaglutide side effects, including kidney stones, may vary.